These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26284823)

  • 1. Lenalidomide is safe and active in Waldenström macroglobulinemia.
    Fouquet G; Guidez S; Petillon MO; Louni C; Ohyba B; Dib M; Poulain S; Herbaux C; Martin A; Thielemans B; Brice P; Choquet S; Bakala J; Bories C; Demarquette H; Nudel M; Tournilhac O; Arnulf B; LeGouill S; Morel P; Banos A; Karlin L; Salles G; Leblond V; Leleu X
    Am J Hematol; 2015 Nov; 90(11):1055-9. PubMed ID: 26284823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
    Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
    Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
    J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
    Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
    Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
    Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Waldenstrom's macroglobulinemia with thalidomide.
    Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P
    J Clin Oncol; 2001 Aug; 19(16):3596-601. PubMed ID: 11504741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
    Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
    Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
    Richardson P; Jagannath S; Hussein M; Berenson J; Singhal S; Irwin D; Williams SF; Bensinger W; Badros AZ; Vescio R; Kenvin L; Yu Z; Olesnyckyj M; Zeldis J; Knight R; Anderson KC
    Blood; 2009 Jul; 114(4):772-8. PubMed ID: 19471019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
    Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
    Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
    Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
    Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
    Schey SA; Morgan GJ; Ramasamy K; Hazel B; Ladon D; Corderoy S; Jenner M; Phekoo K; Boyd K; Davies FE
    Br J Haematol; 2010 Aug; 150(3):326-33. PubMed ID: 20553268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
    Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
    Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
    Wendtner CM; Hallek M; Fraser GA; Michallet AS; Hillmen P; Dürig J; Kalaycio M; Gribben JG; Stilgenbauer S; Buhler A; Kipps TJ; Purse B; Zhang J; De Bedout S; Mei J; Chanan-Khan A
    Leuk Lymphoma; 2016; 57(6):1291-9. PubMed ID: 26763349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
    Pönisch W; Heyn S; Beck J; Wagner I; Mohren M; Hoffmann FA; Lange T; Schmalfeld M; Zehrfeld T; Schwarzer A; Winkelmann C; Edelmann T; Röhrborn R; Hebenstreit K; Al-Ali HK; Jäkel N; Niederwieser D
    Br J Haematol; 2013 Jul; 162(2):202-9. PubMed ID: 23692564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Very low-dose lenalidomide therapy for elderly multiple myeloma patients].
    Minagawa K; Kawano H; Suzuki T; Inagaki T; Kishi M; Hirata T; Kimura S; Takechi M; Koide T; Iwai M; Katayama Y; Matsui T
    Rinsho Ketsueki; 2013 May; 54(5):457-62. PubMed ID: 23727684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
    Ghobrial IM; Siegel DS; Vij R; Berdeja JG; Richardson PG; Neuwirth R; Patel CG; Zohren F; Wolf JL
    Am J Hematol; 2016 Jun; 91(4):400-5. PubMed ID: 26800393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of pomalidomide given for patients with advanced solid tumors.
    Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
    Palumbo A; Larocca A; Falco P; Sanpaolo G; Falcone AP; Federico V; Canepa L; Crugnola M; Genuardi M; Magarotto V; Petrucci MT; Boccadoro M
    Leukemia; 2010 May; 24(5):1037-42. PubMed ID: 20376079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.